Amlodipine/benazepril: Fixed dose combination therapy for hypertension

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 1, 2001, Pages 165-178

  Faulkner, MA ^a   Hilleman, D E ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

Amlodipine benazepril; Fixed dose combination therapy; Hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANTICOAGULANT AGENT; ATENOLOL; BENAZEPRIL; BENAZEPRILAT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CIMETIDINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; NAPROXEN; NIFEDIPINE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RENIN; SALBUTAMOL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; EDEMA; FIRST PASS EFFECT; HEADACHE; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTENSION; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; VERTIGO;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; BLOOD PRESSURE; CLINICAL TRIALS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 0035024930     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.1.165     Document Type: Article

References (55)

1. Overview of JNC VI: New directions in the management of hypertension and cardiovascular risk
2. Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960-1991
3. Hypertension and vascular disease: The need for more intensive blood pressure reduction
4. Low-dose antihypertensive combination therapy: Its rationale and role in cardiovascular risk management
5. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo
6. Critical assessment of combination therapy development
7. Present and future role of combination treatment in hypertension
8. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
9. Cardiac effects of combination therapy
10. Combination antihypertensive therapy: Does it have a role in rational therapy?
11. The rationale for low-dose combination therapy in cardiovascular risk management
12. Combination in the treatment of hypertension: ACE inhibitors and calcium antagonists
13. Pharmacological aspects of calcium channel blockers
14. Unique pharmacologic properties of amlodipine
15. The unique binding properties of amlodipine: A long-acting calcium antagonist
16. High blood pressure and calcium antagonism
17. The pharmacological properties of lipophilic calcium antagonists
18. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and congestive heart failure
19. The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension
20. The pharmacokinetics of benazepril relative to other ACE inhibitors
21. Pharmacokinetic interactions study between benazepril and amlodipine in healthy subjects
22. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily
23. Amlodipine pharmacokinetics in healthy volunteers
24. Clinical pharmacokinetics of amlodipine
25. The metabolism and pharmacokinetics of amlodipine in humans and animals
26. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril HC1 (CGS 14 824 A) in healthy volunteers after single and repeated administration
27. Pharmacokinetics of a new angiotensin converting enzyme inhibitor, benazepril hydrochloride, in special populations
28. The pharmacokinetic profile of amlodipine
29. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension
30. Benazepril, an angiotensin converting enzyme inhibitor: Drug interaction with salbutamol and bronchial response to histamine in normal subjects
31. The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers
32. Effect of grapefruit juice on the pharmacokinetics of amlopidine in healthy volunteers
33. Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements
34. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: A potentially life threatening interaction
35. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia
36. Lithium and angiotensin-converting enzyme inhibitors: Evaluation of a potential interaction
37. Fixed combination of benazepril and low-dose amlodipine in the treatment of mild to moderate essential hypertension: Evaluation by 24-hour non-invasive ambulatory blood pressure monitoring
38. Fixed-dose combination vs. monotherapy in hypertension: A meta-analysis evaluation
39. Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone
40. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebo-controlled, parallel-group study
41. Treatment of patients with essential hypertension: Amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg and placebo
42. Effect of benazepril plus amlodipine vs. benazepril alone on urinary albumin excretion in hypertensive patients with Type II diabetes and microalbuminuria
43. Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines
44. Safety profile of benazepril in essential hypertension
45. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring
46. Therapeutic coverage: Reducing the risks of partial compliance
47. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS 38
48. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM
49. Proteinuria, Albuminuria, Risk Assessment, Detection, Elimination (PARADE): A position paper of the National Kidney Foundation
50. Combined effect of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury
51. Blood pressure control, proteinuria and the progression of renal disease